Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering

  • Graphite Bio Inc GRPH is set to go public on the heels of a $238 million raise less than ten months after getting started with a Series A funding of $45 million
  • Graphite is using a familiar tool to tackle genetic diseases with its CRISPR/Cas9 technology.
  • Graphite is looking to enroll 15 adults in the GPH101 Phase 1/2 trial, hoping to launch by mid-2021, with initial proof-of-concept data expected by the end of 2022.
  • According to the SEC S-1 filing, Graphite plans to spend about $90 million of its IPO funds on this Phase 1/2 trial, with another $40 million going to push through IND studies for each of their other two programs in X-linked severe combined immunodeficiency and Gaucher disease. 
  • An additional $80 million is to be earmarked for other preclinical candidates.
  • Graphite has set a launch price of $17 per share and will trade on NASDAQ under the ticker GRPH.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsIPOsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!